Trial Profile
An Open-Label Drug-Drug Interaction Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of JNJ-31001074 in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 May 2010
Price :
$35
*
At a glance
- Drugs Bavisant (Primary) ; Ketoconazole
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Jan 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 31 Oct 2009 Planned end date changed from 1 Nov 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 18 Jun 2009 New trial record